ArticleToxicology reports2026
Assessing the hepatic and renal parameters of breast cancer patient blood samples before and after chemotherapy.
Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common malignancy in women, with chemotherapy as a fundamental treatment despite its potential to cause hepatotoxicity and nephrotoxicity. Although routine assessment of organ function is customary, the predictive value of composite liver-kidney biomarkers for post-chemotherapy survival remains inadequately investigated. This retrospective study sought to assess the influence of chemotherapy on hepatic and renal parameters in 132 BC patients treated at King Abdullah University Hospital (KAUH) in Jordan from January 2011 to April 2025, with a particular focus on the prognostic relevance of the Albumin-Creatinine Ratio (ACR), Alkaline Phosphatase-to-Creatinine Ratio (ALP/Cr), and Albumin-Bilirubin (ALBI) score. Liver and kidney function tests were evaluated pre- and post-four chemotherapy cycles utilizing Wilcoxon signed-rank tests, Kaplan-Meier survival curves, and Cox proportional hazards regression. Post-treatment analysis demonstrated a moderate yet statistically significant reduction in total protein (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.